Who to call at CNS Pharmaceuticals, Inc., and when
Fundz watches for the moments CNS Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day CNS Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CNS Pharmaceuticals, Inc., from your own LinkedIn network
CNS Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
cnspharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
CNS Pharmaceuticals stockholders approved amendments to the 2020 Equity Plan at the September 30, 2026 Annual Meeting, increasing authorized shares by 650,000 to a total of 765,061 shares available for equity compensation, enhancing the company's ability to incentivize employees and attract talent.
Key Takeaways
Stockholders approved a 650,000 share increase to the 2020 Equity Plan at the Annual Meeting on September 30, 2026
Total authorized shares under the plan now stands at 765,061 shares
2 more takeaways
Related Filings (1)
1 more filing from CNS Pharmaceuticals, Inc. in the last 90 days
Filing Overview
What This Means
CNS Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.